What did the Phase 2 trial show
The study divided 85,223 patients with obesity and 596,045 patients with type 2 diabetes into two groups: Those who had been prescribed semaglutide and those who had not
Standard Dose 200-600 mcg per day via subcutaneous injection, or 1-2 mg two to three times per week
Semaglutide remains effective long-term, but patients may experience ongoing digestive effects, potential muscle loss, and rare risks that require monitoring
Periodically monitor blood chemistries, vital signs, plasma carnitine concentrations, and overall clinical condition
Addressing the unique challenges posed by chronic wounds in the aged population will require interdisciplinary collaboration to advance our understanding of skin aging and wound healing mechanisms